BioTelemetry, Inc.
BEAT
BEAT was delisted on the 8th of February, 2021.
0 hedge funds and large institutions have $0 invested in BioTelemetry, Inc. in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $116K → $0 (-$116K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Logan Capital Management
Newtown Square,
Pennsylvania
|
-$116K |
BEAT Hedge Fund Activity: Q2 2021 in Review
0 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in BioTelemetry, Inc. (BEAT) for Q2 2021, worth a combined $0 — down 100% from $116K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BEAT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Logan Capital Management, exiting entirely with an estimated $116K sold.
- 0 institutional investors held BioTelemetry, Inc. (BEAT) as of Q2 2021, down from 1 in Q1 2021.
- Funds reported $0 of BioTelemetry, Inc. stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new BioTelemetry, Inc. positions in Q2 2021 and 1 closed out, a net change of -1 holder.
- The largest BioTelemetry, Inc. seller in Q2 2021 was Logan Capital Management, an estimated $116K sold.
Based on aggregated 13F filings for Q2 2021.